Research on Prosecution-Defense Consultation in the Leniency System for Admission of Guilt and Acceptance of Punishment
Science of Law Journal · 2026 · 5 (1)
DOI: 10.23977/law.2026.050113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science of Law Journal, 2026.
Abstract (Originalsprache)
: Prosecution-defense consultation is fundamental to the Leniency System for Admission of Guilt and Acceptance of Punishment, rooted in cooperative justice and aimed at respecting the accused’s status while balancing procedural and substantive justice. Its necessity stems from the need to resolve surging caseloads by shifting from adversarial to cooperative litigation. Despite the system’s pilot conclusion, legal provisions on consultation remain unclear. Practical implementation reveals issues like information asymmetry, inconsistent sentencing standards, and procedural ambiguities. Defense counsel often face restricted file access, hindering meaningful negotiation. These problems risk reducing consultation to mere formality. This paper examines these dilemmas and proposes reforms: legislating clear sentencing negotiation rules, mandating evidence disclosure, substantiating legal aid functions, and strengthening judicial review of consultation procedures. These measures aim to ensure equal dialogue and optimize the balance between judicial efficiency and justice.
Zitieren
APA
(2026). Research on Prosecution-Defense Consultation in the Leniency System for Admission of Guilt and Acceptance of Punishment. Science of Law Journal, 5(1). https://doi.org/10.23977/law.2026.050113
Vancouver
Research on Prosecution-Defense Consultation in the Leniency System for Admission of Guilt and Acceptance of Punishment. Science of Law Journal. 2026;5(1). doi:10.23977/law.2026.050113
BibTeX
@article{euvimed2026,
title = {Research on Prosecution-Defense Consultation in the Leniency System for Admission of Guilt and Acceptance of Punishment},
journal = {Science of Law Journal},
year = {2026},
volume = {5},
number = {1},
doi = {10.23977/law.2026.050113}
}
EUVIMED